Bronchiolitis Obliterans Syndrome Market 規模およびシェア分析 - 成長トレンドおよび予測 (2024 - 2031)
Bronchiolitis Obliterans Syndrome Market is segmented By Therapy (Budesonide/Formoterol, Montelukast, N-acetylcysteine), By Drug Class (Macrolide Antibiotics, Corticosteroids, Immunosuppressive Drugs), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD Million) for the above-mentioned segments.
Bronchiolitis Obliterans Syndrome Market Size
市場規模（米ドル） Mn
CAGR4.1%
| 調査期間 | 2024 - 2031 |
| 推定基準年 | 2023 |
| CAGR | 4.1% |
| 市場の集中度 | Medium |
| 主要プレイヤー | Zambon Pharma, Incyte Corporation, Genentech, GlaxoSmithKline, Altavant Sciences and Among Others. |
please let us know !
Bronchiolitis Obliterans Syndrome Market Analysis
The bronchiolitis obliterans syndrome market is estimated to be valued at USD 60.37 Mn in 2024 and is expected to reach USD 79.93 Mn by 2031, growing at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2031. The prevalence of bronchiolitis obliterans syndrome (BOS) is increasing which is driving the demand for effective therapeutics. With no approved drug therapy currently available for BOS, the pipeline drugs in late-stage clinical trials holds significant potential to capture market share if approved.